Rani Therapeutics Holdings (RANI) Total Non-Current Liabilities (2020 - 2021)

Rani Therapeutics Holdings' (RANI) quarterly Total Non-Current Liabilities came in at $2.6 million in Q4 2021, down 65.8% year-on-year from $7.7 million in Q4 2020, and down 49.71% quarter-over-quarter from $5.2 million in Q3 2021.

Rani Therapeutics Holdings (RANI) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends

Rani Therapeutics Holdings' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $2.6 million for Q4 2021.

  • On a quarterly basis, Total Non-Current Liabilities fell 65.8% year-over-year to $2.6 million in Q4 2021; TTM through Dec 2021 was $2.6 million, a 65.8% decrease from a year earlier, with the FY2021 full-year figure at $2.6 million, down 65.8% from the prior year.
  • Total Non-Current Liabilities slipped to $2.6 million in Q4 2021 per RANI's latest filing, from $5.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $9.4 million in Q2 2021 and bottomed at $2.6 million in Q4 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Rani Therapeutics Holdings 160.20 Mn 167.33 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2021 2.64 Mn
Sep 30, 2021 5.25 Mn
Jun 30, 2021 9.36 Mn
Dec 31, 2020 7.72 Mn